Baxter International has acquired AesRx, LLC, a private U.S. biopharma company focused on orphan drug targets. With the acquisition Baxter gains Aes-103, an investigational prophylactic treatment in Phase II development for sickle cell disease (SCD). Baxter made an initial payment and may make additional future payments based on development, regulatory and commercial milestones. Financial details were not disclosed.   Early studies indicate the compound may reduce the sickling of red blood cells...